DANIELLE K EMMET
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation NEW YORK, NY NPI 1285253161
Browse related groups: Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation NY EMD Serono, Inc. All categories
General Payments — all program years on this page
$180.76
- Category: General Payments
- Program years: PY2024
- Record count: 8
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $180.76 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $180.76 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $73.77 | 3 |
| CATALYST PHARMACEUTICALS, INC. | $46.89 | 2 |
| Alexion Pharmaceuticals, Inc. | $25.32 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.58 | 1 |
| Acerta Pharma LLC | $13.20 | 1 |
By program year
| Program year | Amount | Records |
|---|---|---|
| 2024 | $180.76 | 8 |
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1094030933 | Alexion Pharmaceuticals, Inc. | $25.32 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105509872 | AstraZeneca Pharmaceuticals LP | $13.20 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120253459 | EMD Serono, Inc. | $23.23 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120253463 | EMD Serono, Inc. | $26.59 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120253465 | EMD Serono, Inc. | $23.95 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1137540339 | Takeda Pharmaceuticals U.S.A., Inc. | $21.58 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1144447624 | CATALYST PHARMACEUTICALS, INC. | $24.89 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1144447626 | CATALYST PHARMACEUTICALS, INC. | $22.00 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.